<info type="SequenceVariant">Polymorphisms</info> of the <info type="GeneOrGeneProduct">DNA mismatch repair gene HMSH2</info> in <info type="DiseaseOrPhenotypicFeature">breast cancer</info> <info type="DiseaseOrPhenotypicFeature">occurence</info> and <info type="DiseaseOrPhenotypicFeature">progression</info>.

The response of the <info type="CellLine">cell</info> to <info type="ChemicalEntity">DNA damage</info> and its ability to maintain <info type="DiseaseOrPhenotypicFeature">genomic stability</info> by <info type="ChemicalEntity">DNA repair</info> are crucial in preventing <info type="DiseaseOrPhenotypicFeature">cancer initiation</info> and <info type="DiseaseOrPhenotypicFeature">progression</info>. Therefore, <info type="SequenceVariant">polymorphism</info> of <info type="GeneOrGeneProduct">DNA repair genes</info> may affect the process of <info type="DiseaseOrPhenotypicFeature">carcinogenesis</info>. The importance of <info type="GeneOrGeneProduct">genetic variability</info> of the components of <info type="GeneOrGeneProduct">mismatch repair (MMR)</info> <info type="GeneOrGeneProduct">genes</info> is well documented in <info type="DiseaseOrPhenotypicFeature">colorectal cancer</info>, but little is known about its role in <info type="DiseaseOrPhenotypicFeature">breast cancer</info>. <info type="GeneOrGeneProduct">hMSH2</info> is one of the crucial <info type="GeneOrGeneProduct">proteins</info> of <info type="GeneOrGeneProduct">MMR</info>. We performed a <info type="CellLine">case-control study</info> to test the association between two <info type="SequenceVariant">polymorphisms</info> in the <info type="GeneOrGeneProduct">hMSH2 gene</info>: an <info type="SequenceVariant">A --> G transition</info> at 127 position producing an <info type="SequenceVariant">Asn --> Ser substitution</info> at codon 127 (the <info type="SequenceVariant">Asn127Ser polymorphism</info>) and a <info type="SequenceVariant">G --> A transition</info> at 1032 position resulting in a <info type="SequenceVariant">Gly --> Asp change</info> at codon 322 (the <info type="SequenceVariant">Gly322Asp polymorphism</info>) and <info type="DiseaseOrPhenotypicFeature">breast cancer risk</info> and <info type="DiseaseOrPhenotypicFeature">cancer progression</info>. Genotypes were determined in <info type="CellLine">DNA from peripheral blood lymphocytes</info> of 150 <info type="DiseaseOrPhenotypicFeature">breast cancer patients</info> and 150 <info type="DiseaseOrPhenotypicFeature">age-matched women</info> (<info type="CellLine">controls</info>) by <info type="ChemicalEntity">restriction fragment length polymorphism</info> and <info type="ChemicalEntity">allele-specific PCR</info>. We did not observe any correlation between studied <info type="SequenceVariant">polymorphisms</info> and <info type="DiseaseOrPhenotypicFeature">breast cancer progression</info> evaluated by <info type="DiseaseOrPhenotypicFeature">node-metastasis</info>, <info type="DiseaseOrPhenotypicFeature">tumor size</info> and <info type="DiseaseOrPhenotypicFeature">Bloom-Richardson grading</info>. A strong association between <info type="DiseaseOrPhenotypicFeature">breast cancer occurrence</info> and the <info type="GeneOrGeneProduct">Gly/Gly phenotype</info> of the <info type="SequenceVariant">Gly322Asp polymorphism</info> (odds ratio 8.39; 95% confidence interval 1.44-48.8) was found. Therefore, <info type="GeneOrGeneProduct">MMR</info> may play a role in the <info type="DiseaseOrPhenotypicFeature">breast carcinogenesis</info> and the <info type="SequenceVariant">Gly322Asp polymorphism</info> of the <info type="GeneOrGeneProduct">hMSH2 gene</info> may be considered as a potential marker in <info type="DiseaseOrPhenotypicFeature">breast cancer</info>.